MTVA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to MetaVia's net margin of -49.65%. MetaVia's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

MetaVia has a consensus price target of $15.50, signalling upside risk potential of 1784.27%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that MetaVia has higher upside potential than NovaBay Pharmaceuticals, analysts believe MetaVia is more attractive than NovaBay Pharmaceuticals.

MetaVia has a beta of 0.217, which suggesting that the stock is 78.329% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. MetaVia's net income of -$5.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, MetaVia's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat Oragenics's return on equity of --.

MetaVia has a consensus price target of $15.50, signalling upside risk potential of 1784.27%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 407.61%. Given that MetaVia has higher upside potential than Oragenics, analysts believe MetaVia is more attractive than Oragenics.

MetaVia has a beta of 0.217, which suggesting that the stock is 78.329% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. MetaVia's net income of -$5.2M is lower than Oragenics's net income of -$3.3M. Notably, MetaVia's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 1.23x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat Palatin Technologies's return on equity of --.

MetaVia has a consensus price target of $15.50, signalling upside risk potential of 1784.27%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3281.64%. Given that Palatin Technologies has higher upside potential than MetaVia, analysts believe Palatin Technologies is more attractive than MetaVia.

MetaVia has a beta of 0.217, which suggesting that the stock is 78.329% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. MetaVia's net income of -$5.2M is higher than Palatin Technologies's net income of --. Notably, MetaVia's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to MetaVia's net margin of --. MetaVia's return on equity of -- beat Theriva Biologics's return on equity of --.

MetaVia has a consensus price target of $15.50, signalling upside risk potential of 1784.27%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 322.27%. Given that MetaVia has higher upside potential than Theriva Biologics, analysts believe MetaVia is more attractive than Theriva Biologics.

MetaVia has a beta of 0.217, which suggesting that the stock is 78.329% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

MetaVia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

MetaVia quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. MetaVia's net income of -$5.2M is lower than Theriva Biologics's net income of -$4.4M. Notably, MetaVia's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.